Trading Signals: PSTI Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Thu. Mar. 25, 2021)(Pluristem Therapeutics Inc.)
| PSTI latest price $15.0000 (5.63%) ($14.2000 - $15.1000) on Tue. Sep. 28, 2010. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.01% (three month average) | RSI | 75 | Latest Price | $15.0000(5.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | PSTI advances 1.4% a day on average for past five trading days. | Weekly Trend | PSTI advances 11% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support PSTI advance at 0% a week (0% probability) IWM(18%) QQQ(17%) JNK(16%) SPY(16%) VWO(16%) | Factors Impacting PSTI price | PSTI will decline at least -2.505% in a week (0% probabilities). TLT(-7%) TIP(-4%) SHY(-4%) GLD(0%) IGOV(1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.505% (StdDev 5.01%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $14.18(5.78%) | 10 Day Moving Average | $14.07(6.61%) | 20 Day Moving Average | $12.68(18.3%) | To recent high | -7.4% | To recent low | 48.5% | Market Cap | $280m | | | | Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel. |